Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. So, we have made a very big advance ...
Chordoma is a rare tumor characterized by poor prognosis, limited therapeutic options, and a high rate of recurrence. Despite ...
Dr S. Shahzad Mustafa describes how the upcoming 2025 American College of Allergy, Asthma and Immunology Annual Scientific Meeting will feature an exciting and comprehensive agenda, particularly ...
ORLANDO, Fla. — A novel topical therapy for axial hyperhidrosis approved by the FDA in June 2024 is among the increasing number of therapeutic options and new protocols for existing options to improve ...
Since patients with refractory Dermatomyositis (DM) may not respond to existing treatment options, there remains an unmet medical need for more therapeutic alternatives. There are now several drug ...